US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Gilead Sciences (NQ:GILD)

144.63 -0.11 (-0.08%)
Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
78 79 Next >
News headline image
Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies
From Gilead Sciences, Inc.
Via Business Wire
News headline image
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report ↗
ICER's 2023 report highlights five drugs with unsupported price increases, leading to $815 million in excess costs for U.S. payers. Discover key findings and trends. 
Via Benzinga
News headline image
Gilead’s Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis
From Gilead Sciences, Inc.
Via Business Wire
News headline image
What Analysts Are Saying About Gilead Sciences Stock ↗
 
Via Benzinga
News headline image
Looking At Gilead Sciences's Recent Unusual Options Activity ↗
 
Via Benzinga
News headline image
Price Over Earnings Overview: Gilead Sciences ↗
 
Via Benzinga
News headline image
Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing ↗
Gilead's once-yearly injectable lenacapavir shows promising results in HIV prevention, with a 96% reduction in infections and plans for regulatory filings by 2027. 
Via Benzinga
News headline image
Kite’s Yescarta® Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Longest Follow-Up Data Reported for Kite’s Tecartus® CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits
From Gilead Sciences, Inc.
Via Business Wire
News headline image
26 Analysts Assess Gilead Sciences: What You Need To Know ↗
 
Via Benzinga
News headline image
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead. ↗
The companies held competing events on Sunday to discuss their multiple myeloma treatments. 
Via Investor's Business Daily
News headline image
Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients ↗
Arcellx's Phase 2 trial of anito-cel in relapsed multiple myeloma reveals high response rates and manageable safety, with durable patient outcomes. 
Via Benzinga
News headline image
Kite Presents New Data Underscoring Curative Potential of Yescarta® in Relapsed/Refractory Large B-cell Lymphoma at ASH
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead and Tubulis Enter Into Exclusive Option and License Agreement to Develop ADC Candidate for Select Solid Tumor Target
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Announces New England Journal of Medicine Publication of PURPOSE 2 Results
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease ↗
Gilead shares data from its Phase 3 ASSURE study, showing 81% of PBC patients treated with Livdelzi achieved a composite response with continued safety. 
Via Benzinga
News headline image
Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Trump's Victory Spurs $50B Corporate Bond Surge As Tax Cut Optimism Drives Borrowing Costs To 25-Year Low ↗
The surge in corporate borrowing is driven by a rally in credit and equity markets, which has pushed borrowing costs to historic lows. 
Via Benzinga
Topics Government
News headline image
Gilead Prices $3.5 Billion of Senior Unsecured Notes
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Scientific Leadership Spotlighted as Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline
From Gilead Sciences, Inc.
Via Business Wire
News headline image
3 Spectacular High-Yield Dividend Stocks to Buy in November ↗
High yields aren't a warning indicator with these three stocks. 
Via The Motley Fool
News headline image
Gilead Sciences to Present at Upcoming Investor Engagements
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks ↗
The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers Squibb, Gilead Sciences, and Sanofi, despite challenges for Novo Nordisk and... 
Via Benzinga
News headline image
Stock Market Surges To Highs On Trump Election; Fed Cuts Rates, Palantir Soars: Weekly Review ↗
A Fed rate cut and a slew of big earnings reports filled out a busy week. 
Via Investor's Business Daily
Topics Economy Government
News headline image
Smaller Cap Biotechs Are In Season: How Are We Doing? ↗
SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range. 
Via Talk Markets
News headline image
HIV Drugmaker Gilead Reports Strongest Quarterly Performance Of 2024, Analysts Boost Price Target On Raised Outlook ↗
Gilead stock surges after Q3 earnings beat estimates and raised FY 2024 guidance, with strong HIV drug sales and analyst upgrades boosting investor confidence. 
Via Benzinga
Topics Earnings
News headline image
Nasdaq 100 Extends Record Levels Ahead Of Fed Meeting, Tesla Hits 26-Month Highs, Small Caps Stall: What's Driving Markets Thursday? ↗
After Wednesday’s “everything rally” spurred by the election results, investors took a less euphoric approach on Thursday ahead of the Federal Open Market Committee (FOMC) meeting. The Fed is widely... 
Via Benzinga
Topics Economy
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
78 79 Next >